Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
Status:
Recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
A Randomized, Double-blind, Multiple-Dose, Two-Cycle, Parallel-Group, Bioequivalence pretrial
of Daunorubicin Cytarabine liposome for Injection in older, naive patients with Acute Myeloid
Leukemia (AML).